119 related articles for article (PubMed ID: 37024023)
1. Elevated exosome-transferrable lncRNA EPB41L4A-AS1 in CD56
Chai W; Wang X; Lu Z; Zhang S; Wang W; Wang H; Chen C; Yang W; Cheng H; Wang H; Feng J; Yang S; Li Q; Song W; Jin F; Zhang H; Su Y; Gui J
Clin Immunol; 2023 May; 250():109322. PubMed ID: 37024023
[TBL] [Abstract][Full Text] [Related]
2. LncRNA EPB41L4A-AS1 regulates glycolysis and glutaminolysis by mediating nucleolar translocation of HDAC2.
Liao M; Liao W; Xu N; Li B; Liu F; Zhang S; Wang Y; Wang S; Zhu Y; Chen D; Xie W; Jiang Y; Cao L; Yang BB; Zhang Y
EBioMedicine; 2019 Mar; 41():200-213. PubMed ID: 30796006
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells.
Keating SE; Zaiatz-Bittencourt V; Loftus RM; Keane C; Brennan K; Finlay DK; Gardiner CM
J Immunol; 2016 Mar; 196(6):2552-60. PubMed ID: 26873994
[TBL] [Abstract][Full Text] [Related]
4. A long noncoding RNA positively regulates CD56 in human natural killer cells.
Zhang R; Ni F; Fu B; Wu Y; Sun R; Tian Z; Wei H
Oncotarget; 2016 Nov; 7(45):72546-72558. PubMed ID: 27713137
[TBL] [Abstract][Full Text] [Related]
5. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
[TBL] [Abstract][Full Text] [Related]
7. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression.
Song H; Li D; Wang X; Fang E; Yang F; Hu A; Wang J; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
J Hematol Oncol; 2020 Mar; 13(1):24. PubMed ID: 32216806
[TBL] [Abstract][Full Text] [Related]
8. The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.
Harlin H; Hanson M; Johansson CC; Sakurai D; Poschke I; Norell H; Malmberg KJ; Kiessling R
J Immunol; 2007 Oct; 179(7):4513-9. PubMed ID: 17878347
[TBL] [Abstract][Full Text] [Related]
9. Interferon-γ production by tubulointerstitial human CD56
Law BMP; Wilkinson R; Wang X; Kildey K; Lindner M; Rist MJ; Beagley K; Healy H; Kassianos AJ
Kidney Int; 2017 Jul; 92(1):79-88. PubMed ID: 28396119
[TBL] [Abstract][Full Text] [Related]
10. Low-frequency, exhausted immune status of CD56
Pan Z; Zhao R; Shen Y; Liu K; Xue W; Liang C; Peng M; Hu P; Chen M; Xu H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108369. PubMed ID: 34844872
[TBL] [Abstract][Full Text] [Related]
11. Imbalance between CD56+bright and CD56+dim natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation.
Yamagiwa S; Sato Y; Ichida T; Setsu T; Tominaga K; Kamimura H; Tsuchiya A; Takamura M; Matsuda Y; Aoyagi Y
Biomed Res; 2014; 35(3):177-84. PubMed ID: 24942856
[TBL] [Abstract][Full Text] [Related]
12. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
13. CD56
Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
[TBL] [Abstract][Full Text] [Related]
15. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
16. IncRNA EPB41L4A-AS1 Mitigates the Proliferation of Non-Small-Cell Lung Cancer Cells through the miR-105-5p/GIMAP6 Axis.
Dong B; Zhang F; Zhang W; Gao Y
Crit Rev Eukaryot Gene Expr; 2023; 33(2):27-40. PubMed ID: 36734855
[TBL] [Abstract][Full Text] [Related]
17. Impaired circulating CD56
Jiang Y; Chen Y; Chen L; Yao W; Guan J; Liu X; Wei X; Lin X
Hum Immunol; 2020 Jan; 81(1):32-40. PubMed ID: 31735440
[TBL] [Abstract][Full Text] [Related]
18. Distinct natural killer cells in HIV-exposed seronegative subjects with effector cytotoxic CD56(dim) and CD56(bright) cells and memory-like CD57⁺NKG2C⁺CD56(dim) cells.
Lima JF; Oliveira LM; Pereira NZ; Mitsunari GE; Duarte AJ; Sato MN
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):463-71. PubMed ID: 25230289
[TBL] [Abstract][Full Text] [Related]
19. The Increased Ratio of Blood CD56
Ming B; Wu T; Cai S; Hu P; Tang J; Zheng F; Ye C; Dong L
J Immunol Res; 2020; 2020():7523914. PubMed ID: 32695834
[TBL] [Abstract][Full Text] [Related]
20. Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.
Domaica CI; Fuertes MB; Uriarte I; Girart MV; Sardañons J; Comas DI; Di Giovanni D; Gaillard MI; Bezrodnik L; Zwirner NW
PLoS One; 2012; 7(12):e51677. PubMed ID: 23240056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
